Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2026.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals reported strong annual results for FY26 ended March 31, 2026. Consolidated revenue grew 59% to Rs 632.63 crore from Rs 398.25 crore, while net profit more than doubled to Rs 121.53 crore from Rs 58.34 crore. Standalone revenue jumped 175% to Rs 106.09 crore. The company expanded its subsidiary network through acquisitions of Apnar Pharma (75% stake in Jan 2026) and Zoraya Pharmaceuticals LLC (51% in Nov 2025). Statutory auditors Pankaj R. Shah & Associates issued an unmodified opinion. Company Secretary Vinay Kumar Mishra resigned effective June 10, 2026, and Sharp & Tannan Associates was appointed as the new internal auditor for FY 2026-27. Cash and cash equivalents declined to Rs 45.55 crore from Rs 105.36 crore at year-start due to capex and acquisitions.
Strong growth trajectory with net profit more than doubling reflects successful integration of recent acquisitions and organic expansion. However, the upcoming KMP change may require investor attention. The unmodified audit opinion provides confidence in financial reporting quality.